新泰医药 MDGL 深 沪
等待开盘 05-12 09:30:00 美东时间
497.03
-13.380
-2.62%
华盛通- 最 高559.00
- 今 开511.32
- 成交量 30.77万股
- 最 低 493.57
- 昨 收 510.41
- 总市值 850.09万
- 52周最高 615.00
- 市盈率 静 --
- 换手率 1798.81%
- 52周最低 265.00
- 委 比 97.65%
- 总股本 1.71万
- 历史最高 615.00
- 量 比 1.12
- 振 幅 12.82%
- 历史最低 1.10
- 每 手 1
- 风险率 96.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Madrigal Pharmaceuticals Announces Exclusive Global License Agreement With Arrowhead Pharmaceuticals For ARO-PNPLA3
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly
05-05 20:02
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Madrigal Pharmaceuticals (NASDAQ:MDGL) has been analyzed by 5 analysts in the l...
02-21 04:01
Earnings Scheduled For February 19, 2026
Companies Reporting Before The Bell • Deere (NYSE:DE) is expected to report qua...
02-19 19:11
Earnings Preview For Madrigal Pharmaceuticals
Madrigal Pharmaceuticals (NASDAQ:MDGL) is set to give its latest quarterly earn...
02-18 23:01
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight
Cantor Fitzgerald analyst Prakhar Agrawal upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Neutral to Overweight.
2025-11-05 21:19
再创新高！港股创新药ETF(513120)规模突破170亿元，连续4天净流入累计“吸金”超20亿元
Wind数据显示，截至2025年8月8日收盘，港股创新药ETF最新规模首次突破170亿元，达172.67亿元，创成立以来新高。份额方面，港股创新药ETF最新份额...
2025-08-11 09:28
口服GLP-1黑马诞生！石药临床前小分子20.8亿美金出海
（来源：抗体圈） 7月30日，石药集团（1093.HK）宣布，其与纳斯达克上市公司Madrigal Pharmaceuticals（NASDAQ：MDGL）就口...
2025-08-01 09:58
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
The European Medicines Agency's CHMP has recommended approval of resmetirom for treating adults with noncirrhotic MASH with moderate to advanced liver fibrosis, with the European Commission's decision expected in August 2025. If approved, resmetirom would be the first medication for MASH in the EU, following its successful Phase 3 MAESTRO-NASH trial that achieved fibrosis reduction and MASH resolution.
2025-06-20 10:30
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards, including stock options and restricted stock units, to 36 new non-executive employees under its 2023 Inducement Plan. The awards vest over time and aim to incentivize the employees' continued service. The company focuses on novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
2025-06-17 20:05
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Madrigal Pharmaceuticals to Present at the 46th Annual Global Goldman Sachs Health Care Conference on June 11, 2025. The presentation will be webcast live and available for replay. Madrigal focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with Rezdiffra, its FDA-approved medication for MASH with moderate to advanced fibrosis. For more information, visit Madrigal’s Investor Relations page.
2025-06-02 12:00
